While the opioid epidemic has garnered significant attention, the use of methamphetamines
is growing worldwide independent of wealth or region. Following overdose and accidents …

Pulmonary hypertension (PH) is a heterogeneous and fatal disease of the lung vasculature,
where metabolic and mitochondrial dysfunction may drive pathogenesis. Similar to the …

Pulmonary inflammation, which is characterized by the presence of perivascular
macrophages, has been proposed as a key pathogenic driver of pulmonary hypertension …

Pulmonary arterial hypertension (PAH) is a progressive disease in which pulmonary arterial
(PA) endothelial cell (EC) dysfunction is associated with unrepaired DNA damage. BMPR2 …

Rationale: In pulmonary arterial hypertension (PAH), endothelial dysfunction and obliterative
vascular disease are associated with DNA damage and impaired signaling of BMPR2 (bone …

Rationale: Although amphetamines are recognized as “likely” agents to cause drug-and
toxin-associated pulmonary arterial hypertension (PAH),(meth) amphetamine-associated …

Cardiovascular diseases (CVDs) arise from a complex interplay among genomic, proteomic,
and metabolomic abnormalities. Emerging evidence has recently consolidated the presence …

Background: Excessive proliferation and apoptosis resistance of pulmonary artery smooth
muscle cells (PASMCs) are key mechanisms of pulmonary arterial hypertension (PAH) …

Pulmonary arterial hypertension (PAH) is a pulmonary vasculopathy that causes right
ventricular dysfunction and exercise limitation and progresses to death. New findings from …

Severe forms of pulmonary arterial hypertension (PAH) are most frequently the
consequence of a lumen-obliterating angiopathy. One pathobiological model is that the …